|Bid||0.0000 x 2200|
|Ask||0.0000 x 800|
|Day's Range||0.0100 - 0.0112|
|52 Week Range||0.0100 - 1.0700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||10.00|
|Earnings Date||Nov. 09, 2018 - Nov. 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.75|
Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today announced that on March 10, 2020, the Nasdaq Office of General Counsel notified the Company that the Nasdaq Hearing Panel (“Panel”) had determined to delist the Company’s shares from The Nasdaq Stock Market LLC (“Nasdaq”), and that trading in the Company’s common shares will be suspended effective at the open of business on March 12, 2020. Nasdaq will thereafter file a Form 25 with the Securities and Exchange Commission (“SEC”) to effect the formal delisting of the Company’s common stock following the expiration of all applicable Nasdaq procedures.
SAN DIEGO and VANCOUVER, British Columbia, Nov. 07, 2019 -- Sophiris Bio Inc. (NASDAQ: SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class,.